Merck Agrees to Buy Silence Therapeutics for $1.3 Billion
Merck KGaA said it is offering $20 per American depositary share in cash for the U.K. biotech, adding an experimental polycythemia vera medicine to its pipeline.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.